Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cabozantinib (XL184) With Panitumumab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer and Cabozantinib Monotherapy in Subjects With MET Amplified Treatment-Refractory Colorectal Cancer

Trial Profile

Cabozantinib (XL184) With Panitumumab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer and Cabozantinib Monotherapy in Subjects With MET Amplified Treatment-Refractory Colorectal Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabozantinib (Primary) ; Panitumumab (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CaboMAb
  • Most Recent Events

    • 29 Jan 2019 Status changed from recruiting to completed.
    • 05 Jun 2018 Results from a cohort of patients with MET amplification detected in blood presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 26 Apr 2018 According to an Exelixis media release, data from this trial will be presented at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top